Drive was recently awarded a $256,000 Phase 1 SBIR grant from the NSF to help continue development of our novel, aptamer based inhibitors...

Drive Therapeutics of Research Triangle Park received $100,000 to develop a novel nucleic acid therapy to block angiogenesis,...

Doug has agreed to join the team as CEO and help us navigate fundraising, early stage company formation, and relationship formation...

Exciting news out of the University of Louisville.....

As a fledgling biotech startup, we are looking for ways to raise funding and meet potential investors while #stayingathome. We have...